To mimic the clinical PD phenomenon and examine the effect of combination therapy of docetaxel with erlotinib, we established an in vivo erlotinib-resistant model using EGFR-positive pancreatic cancer cell line HPAC. Here, EGFR is linked to familial pancreatic carcinoma.